June 28, 2022
1 minute watch
Source/Disclosures
Published by:
Source: Healio Interview
Disclosures: Krishnan reports leadership roles at Sutro Biopharma; funding of research at his institution by Janssen; consultant/advisory roles with Bristol Myers Squibb, GlaxoSmithKline and Janssen; speaker bureau roles with Amgen, Bristol Myers Squibb, GlaxoSmithKline and Takeda; and the shareholding of Bristol Myers Squibb.
In this video, Amrita KrishnanMD, director of the Judy and Bernard Briskin Center for Multiple Myeloma Research at the City of Hope Cancer Center, discusses major developments in multiple myeloma presented at the ASCO Annual Meeting.
Krishnan highlights new data on chimeric antigen receptor T cells, including indications that CAR T cells have significant growth margin in the multiple myeloma sphere.
“This suggests that we have more room to optimize our CAR-T products in terms of efficacy and time to delivery to the patient,” Krishnan said.
Take home in multiple myeloma
